RMC-4550 is primarily utilized in the field of cancer research and drug development. It functions as a potent and selective inhibitor of SHP2, a protein tyrosine phosphatase involved in various signaling pathways that promote cell growth and survival. By inhibiting SHP2, RMC-4550 helps to disrupt these pathways, making it a valuable tool for studying the role of SHP2 in cancer progression and for evaluating its potential as a therapeutic target. Researchers use this compound to investigate its effects on tumor growth and to explore its efficacy in combination with other cancer therapies, particularly in cancers driven by mutations in the RAS/MAPK pathway. Its application extends to preclinical studies aimed at developing novel treatments for cancers resistant to existing therapies.